PRMA Consulting is offering a selection of case studies that reflect the challenges facing stakeholders when considering market access strategies for rare disease drugs, orphan treatments, and regenerative medicine therapies. The free compilation includes important insight for pharma professionals, including regulatory agency requirements and value proposition challenges.
“Market access strategies for regenerative medicines, and rare and orphan disease treatments are particularly complex. This collection of case studies illustrates some of the challenges and opportunities for manufacturers.” Read more here.
(Source: PRMA Consulting, 2021)